Assessment of a revolving drug fund for essential asthma medicines in Benin

Gildas Agodokpessi, Nadia Aït-Khaled, Martin Gninafon, Leon Tawo, Wilfried Bekou, Christophe Perrin, Karen Bissell, Nils Billo, Donald A. Enarson, Chen Yuan Chiang

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013. Methods: We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008–2013. Results: The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008–2013. Conclusion: The Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.

Original languageEnglish
Article number12
Pages (from-to)1-8
Number of pages8
JournalJournal of Pharmaceutical Policy and Practice
Volume8
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Essential Drugs
Benin
Financial Management
Asthma
Pharmaceutical Preparations
Economics
Nebulizers and Vaporizers
Universal Coverage
Organized Financing
Health Expenditures
Medicine

Keywords

  • Asthma
  • Beclometasone
  • Inhaled corticosteroid
  • Revolving drug fund

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Assessment of a revolving drug fund for essential asthma medicines in Benin. / Agodokpessi, Gildas; Aït-Khaled, Nadia; Gninafon, Martin; Tawo, Leon; Bekou, Wilfried; Perrin, Christophe; Bissell, Karen; Billo, Nils; Enarson, Donald A.; Chiang, Chen Yuan.

In: Journal of Pharmaceutical Policy and Practice, Vol. 8, No. 1, 12, 2015, p. 1-8.

Research output: Contribution to journalArticle

Agodokpessi, G, Aït-Khaled, N, Gninafon, M, Tawo, L, Bekou, W, Perrin, C, Bissell, K, Billo, N, Enarson, DA & Chiang, CY 2015, 'Assessment of a revolving drug fund for essential asthma medicines in Benin', Journal of Pharmaceutical Policy and Practice, vol. 8, no. 1, 12, pp. 1-8. https://doi.org/10.1186/s40545-015-0033-7
Agodokpessi, Gildas ; Aït-Khaled, Nadia ; Gninafon, Martin ; Tawo, Leon ; Bekou, Wilfried ; Perrin, Christophe ; Bissell, Karen ; Billo, Nils ; Enarson, Donald A. ; Chiang, Chen Yuan. / Assessment of a revolving drug fund for essential asthma medicines in Benin. In: Journal of Pharmaceutical Policy and Practice. 2015 ; Vol. 8, No. 1. pp. 1-8.
@article{3f6b5be6235e4cf89f5dfd267c7bc3ff,
title = "Assessment of a revolving drug fund for essential asthma medicines in Benin",
abstract = "Objectives: Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013. Methods: We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008–2013. Results: The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008–2013. Conclusion: The Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.",
keywords = "Asthma, Beclometasone, Inhaled corticosteroid, Revolving drug fund",
author = "Gildas Agodokpessi and Nadia A{\"i}t-Khaled and Martin Gninafon and Leon Tawo and Wilfried Bekou and Christophe Perrin and Karen Bissell and Nils Billo and Enarson, {Donald A.} and Chiang, {Chen Yuan}",
year = "2015",
doi = "10.1186/s40545-015-0033-7",
language = "English",
volume = "8",
pages = "1--8",
journal = "Journal of Pharmaceutical Policy and Practice",
issn = "2052-3211",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Assessment of a revolving drug fund for essential asthma medicines in Benin

AU - Agodokpessi, Gildas

AU - Aït-Khaled, Nadia

AU - Gninafon, Martin

AU - Tawo, Leon

AU - Bekou, Wilfried

AU - Perrin, Christophe

AU - Bissell, Karen

AU - Billo, Nils

AU - Enarson, Donald A.

AU - Chiang, Chen Yuan

PY - 2015

Y1 - 2015

N2 - Objectives: Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013. Methods: We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008–2013. Results: The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008–2013. Conclusion: The Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.

AB - Objectives: Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013. Methods: We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008–2013. Results: The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008–2013. Conclusion: The Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.

KW - Asthma

KW - Beclometasone

KW - Inhaled corticosteroid

KW - Revolving drug fund

UR - http://www.scopus.com/inward/record.url?scp=84983161313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983161313&partnerID=8YFLogxK

U2 - 10.1186/s40545-015-0033-7

DO - 10.1186/s40545-015-0033-7

M3 - Article

AN - SCOPUS:84983161313

VL - 8

SP - 1

EP - 8

JO - Journal of Pharmaceutical Policy and Practice

JF - Journal of Pharmaceutical Policy and Practice

SN - 2052-3211

IS - 1

M1 - 12

ER -